Tetanus Antitoxoid Antibodies

Assess immunity against tetanus by determining levels of circulating antibodies to tetanus toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders

Determination of tetanus toxoid antibodies is of no value in assessing the need for prophylactic or therapeutic management. Immunity declines with age, and boosters are recommended every 10 years.

This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.

Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995; 332(12):761-766. PubMed 7862178

Rose NR. Manual of Clinical Immunology. 5th ed. Washington, DC: ASM Press;1997: 470-472.